Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Quality of Life
4 years
Yes
Peng Yuan, M.D.
Principal Investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
China: Ethics Committee
CH-BC-011
NCT01431053
July 2011
July 2014
Name | Location |
---|